The Company

VetCell is a leading veterinary medical technology company offering a personalised service to vets for the treatment of equine leg injuries and the prevention of lameness. 

VetCell Bioscience was formed in 2002 in partnership with the Royal Veterinary College (RVC) and the Institute for Orthopaedic and Musculoskeletal Science to commercialise regenerative medicine products. The business was acquired in April 2010 by Quy Biosciences Ltd whose plans include expanding the veterinary business worldwide and maximising the intellectual property rights potential for human stem cell tendon treatment.

VetCell's technologies are founded on the pioneering work of Professor Roger Smith and his colleagues at the RVC which developed from the knowledge that Mesenchymal Stem Cells (MSCs) can engraft and selectively differentiate depending on the tissue environment, into specialised tissues such as tendon, ligament, muscle and bone. The result of this therapy, now called 'StemRegen', is that horses return to full work with half the re-injury rate of untreated horses. As well as this, the 'return to performance' rate is 80% versus 40% for conventional treatments. Dream Alliance (below) won the Welsh Grand National following VetCell's stem cell therapy for a severe tendon injury.

The primary thrust of VetCell's near-term business strategy is the development of clinical products and services in the regenerative medicine field. The orthopaedic programme focuses on the treatment of tendon and ligament injuries in the performance horse using a combination of mesenchymal stem cells and various carriers and scaffolds. The company also markets and distributes Equine Platelet Enhancement Therapy (E-PET) developed and manufactured by Pall Corporation, which is a sterile, filter based, method of rapidly preparing a platelet concentrate from blood for use as a wound healing fluid. In addition to these well established products VetCell is conducting and collaborating on research into other wound healing technologies which will lead to further pioneering products in the regenerative medicine field.

VetCell boasts a global approach to the market. StemRegen, the stem cell therapy, is available across Europe and Scandinavia from our European office based in Oxford in collaboration with VLA approved laboratories at Biobest in Edinburgh.

Our US subsidiary company, VetCell Biosciences Inc in collaboration with the Coriell Institute for Medical Research provides the service to veterinary practices in the US and the Americas with the exception of Canada where StemRegen is available via the Atlantic Veterinary College. In Japan the company's research programmes are developed in association with the Japan Racing Association. E-PET, the platelet concentration product, is available Worldwide via our website: www.vetcell.com and also from our European and American offices as well as from our regional distributors. VetCell is constantly looking for further distribution and research links and is expanding both its existing services and its product range across the World.